CINCINNATI--(BUSINESS WIRE)--July 1, 2003--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has been added to the
Russell 2000(R) Index of small-capitalization stocks. The Russell
Indexes were jointly developed by the Frank Russell Company and the
New York Futures Exchange to represent investment-grade equities.
Meridian's inclusion in the Russell Index is a result of the Frank
Russell Company's annual assessment and reconstitution of its U.S.
equity indexes. Final additions and deletions to the Indexes were
announced today and are listed on www.russell.com.
"Meridian's growth in revenues and earnings, plus our long
standing dividend history, has resulted in significant appreciation in
shareholder value and increased daily trading volume. Our inclusion in
the Russell Indexes further enhances our visibility," commented
William J. Motto, Chairman and Chief Executive Officer.
Annual reconstitution of the Russell Indexes captures the 3,000
largest U.S. stocks as of the end of May, ranking them by total market
capitalization to create the Russell 3000(R) Index. The largest 1,000
companies in the ranking are designated the Russell 1000(R) Index,
while the remaining 2,000 companies make up the small-cap Russell 2000
Index. Inclusion in Russell indexes, which are used as benchmarks for
both passive and active investment strategies, is determined strictly
by market capitalization and style attributes.
Meridian is a fully integrated life science company that
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and
offers biopharmaceutical enabling technologies. Utilizing a variety of
methods, these products provide accuracy, simplicity and speed in the
early diagnosis and treatment of common medical conditions, such as
gastrointestinal, viral, urinary and respiratory infections. All
Meridian products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents and specialty biologicals. The Company
markets its products to hospitals, reference laboratories, research
centers, veterinary testing centers and physician offices in more than
60 countries around the world. The Company's shares are traded through
Nasdaq's National Market, symbol VIVO. Meridian's website address is
CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513/271-3700
SOURCE: Meridian Bioscience, Inc.